A study in mice reveals key interactions between proteins involved in fibroblast growth factor signaling and how they contribute to distinct stages of eye lens development.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

The firm believes VVD-159642 has the potential to treat a broad patient population, including those with RAS- and HER2-overexpressed tumors.

Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial ...

and may deliver increased efficacy in combination with other RAS/MAPK pathway inhibitors Approximately 20 percent of all cancers are driven by mutations of the RAS family of genes 1 Vividion ...

Vividion Therapeutics, Inc. has announced that the first patient has been dosed in a Phase I clinical trial evaluating ...

San Diego, California Friday, April 4, 2025, 16:00 Hrs [IST] ...

Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...

Abstract 4367 – ERAS-4001 is a pan-KRAS inhibitor with robust anti-tumor activity in KRAS altered solid tumors Date/Time: Tuesday, April 29, 2025, 9 AM – 12 PM CDT Session: Experimental and Molecular ...

VVD-159642, Vividion's fourth clinical-stage program stemming from its chemoproteomics discovery platform, is designed to improve patient outcomes by inhibiting RAS-PI3Ka, a key signaling pathway ...

Fintel reports that on March 26, 2025, Raymond James initiated coverage of Erasca (NasdaqGS:ERAS) with a Outperform ...